Rheumatology | Page 7 of 37 | Links Medicus Content Curation & Alerts in Medicine

Systematic Review | TNF inhibitors for juvenile idiopathic arthritis‐associated uveitis.

21 Oct, 2022 | 12:55h | UTC

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis – Cochrane Library

Systematic Review | Conservative vs. surgical management for femoro-acetabular impingement.

19 Oct, 2022 | 14:09h | UTC

Conservative vs. Surgical Management for Femoro-Acetabular Impingement: A Systematic Review of Clinical Evidence – Journal of Clinical Medicine

Arthroscopic hip surgery compared with personalised hip therapy in people over 16 years old with femoroacetabular impingement syndrome: UK FASHIoN RCT – Health Technology Assessment

Arthroscopic hip surgery compared with physiotherapy and activity modification for the treatment of symptomatic femoroacetabular impingement: multicentre randomised controlled trial – The BMJ

RCT | Allopurinol does not improve outcomes in patients with ischemic heart disease without previous gout.

13 Oct, 2022 | 13:53h | UTC

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial – The Lancet

Invited Commentary: Xanthine oxidase inhibition for cardiovascular disease prevention – The Lancet

Commentary on Twitter

Despite favorable effects on surrogate endpoints in smaller trials, in an RCT trial of 5,721 pts with CAD, allopurinol did not significantly improve cardiovascular prognosis compared to placebo https://t.co/ITW4HAwI2K @TheLancet pic.twitter.com/EggHM8flle

— Pradeep Natarajan (@pnatarajanmd) October 7, 2022

Under a Creative Commons Attribution (CC BY 4.0) License

RCT | Intravenous immune globulin reduces disease activity in dermatomyositis.

6 Oct, 2022 | 13:48h | UTC

Trial of Intravenous Immune Globulin in Dermatomyositis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

NEJM: trial of IVIG for autoimmune disorder dermatomyositis – MedicalResearch.com

IV Immune Globulin Bests Placebo for Dermatomyositis – Drugs.com

M-A | Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis.

6 Oct, 2022 | 13:37h | UTC

Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis – BMC Rheumatology

RCTs | Effect of Roflumilast cream vs. vehicle cream on chronic plaque psoriasis.

22 Sep, 2022 | 13:06h | UTC

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials – JAMA (free for a limited period)

Editorial: Roflumilast for Chronic Plaque Psoriasis – JAMA

Commentary: Study Suggests Roflumilast May Be Effective As Treatment For Plaque Psoriasis – HCPLive

Commentary on Twitter

Roflumilast cream resulted in better chronic plaque psoriasis clinical status compared with vehicle cream at 8 weeks; further research is needed to compare efficacy with other active treatments and to assess longer-term efficacy and safety. https://t.co/DyGNNjr5ea #Research pic.twitter.com/QnMcChnht6

— JAMA (@JAMA_current) September 21, 2022

RCT | Effect of Tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy.

22 Sep, 2022 | 13:06h | UTC

Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Tocilizumab as a Novel Therapy for Steroid-Dependent Polymyalgia Rheumatica – JAMA (free for a limited period)

Video Editor’s Note: Tocilizumab and Disease Activity in Patients With Polymyalgia Rheumatica Receiving Glucocorticoid Therapy – JAMA

RCT | Deucravacitinib vs. placebo and Apremilast in moderate to severe plaque psoriasis.

20 Sep, 2022 | 13:16h | UTC

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial – Journal of the American Academy of Dermatology

RCT | Methotrexate may increase response rates in patients with uncontrolled gout receiving Pegloticase.

19 Sep, 2022 | 12:38h | UTC

A Randomized Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT): Primary Efficacy and Safety Findings – Arthritis & Rheumatology

Commentary: Data Now Out for Pegloticase-MTX Combo Gout Treatment – MedPage Today (free registration required)

RCT | Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumor necrosis factor inhibitor therapy.

19 Sep, 2022 | 12:35h | UTC

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study – Annals of Rheumatic Diseases

Study finds a higher complication rate after acute coronary syndrome in patients with rheumatic immune‐mediated inflammatory diseases.

15 Sep, 2022 | 13:01h | UTC

Outcomes Following Acute Coronary Syndrome in Patients With and Without Rheumatic Immune‐Mediated Inflammatory Diseases – Journal of the American Heart Association

News Release: Study finds higher complication rate after heart attack in people with autoimmune disease – American Heart Association

M-A of randomized trials | Digital health interventions for musculoskeletal pain conditions.

14 Sep, 2022 | 13:08h | UTC

Digital Health Interventions for Musculoskeletal Pain Conditions: Systematic Review and Meta-analysis of Randomized Controlled Trials – Journal of Medical Internet Research

Phase 2 RCT | Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease.

6 Sep, 2022 | 14:22h | UTC

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Respiratory Medicine

Commentary on Twitter

NEW Research—Pirfenidone slowed the rate of decline of FVC over time in patients with RA-ILD*

Being presented at #ERSCongress, ALERT 3 session, Sept 5 from 13:15 BST

From Joshua Solomon & colleagues https://t.co/Nu8wECECdD

*(please check study limitations) pic.twitter.com/IuRxLDZGd9

— The Lancet Respiratory Medicine (@LancetRespirMed) September 5, 2022

RCT | In patients with rheumatoid arthritis, Tofacitinib is associated with increased risk of infections compared to TNF inhibitors.

1 Sep, 2022 | 11:50h | UTC

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial – Annals of Rheumatic Diseases

Commentary on Twitter

Check out our latest paper on infections in #rheumatoid #arthritis patients from the ORAL Surveillance trial:

▶️ tofacitinib lead to higher infection rates (serious and non-serious) vs TNFi
▶️ increased rates more pronounced in patients aged > 65

🔗 https://t.co/3pVrnzzFWD pic.twitter.com/Kf7p6D0jBD

— Annals of the Rheumatic Diseases (@eular_ARD) August 11, 2022

#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.

30 Aug, 2022 | 12:16h | UTC

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials – The Lancet

News Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology

Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD

[News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.

29 Aug, 2022 | 12:15h | UTC

Allopurinol does not improve cardiovascular outcomes in ischaemic heart disease patients – European Society of Cardiology

Commentary:

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention – TCTMD

No improvement with allopurinol for patients with ischemic heart disease: ALL-HEART – Cardiology Now

Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.

29 Aug, 2022 | 12:11h | UTC

Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK – The Lancet (free registration required)

Commentary: Population-based study: Autoimmune disorders increase risk of cardiovascular disease – MedicalXpress

RCT | Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis.

29 Aug, 2022 | 11:58h | UTC

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

RCT | Olokizumab vs. Placebo or Adalimumab in rheumatoid arthritis.

25 Aug, 2022 | 12:04h | UTC

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Novel IL-6 Blocker Matches Humira in Rheumatoid Arthritis – MedPage Today (free registration required)

Observational study suggests Hydroxychloroquine is associated with increased risk of cardiovascular events compared to Methotrexate in patients with heart failure.

25 Aug, 2022 | 11:56h | UTC

Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Editorial: Hydroxychloroquine: Heart-Throb No More? – Journal of the American College of Cardiology

Commentary: Caution needed with hydroxychloroquine use in older RA patients with heart failure – medwire News

Systematic Review | Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease.

25 Aug, 2022 | 11:55h | UTC

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider – RMD Open

Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach.

24 Aug, 2022 | 14:09h | UTC

Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach – Aging Clinical and Experimental Research

Erosive hand osteoarthritis: latest findings and outlook – Nature Reviews Rheumatology

Efficacy of corticosteroids for hand osteoarthritis – a systematic review and meta-analysis of randomized controlled trials – BMC Musculoskeletal Disorders

ACR Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

#ACR19 – Randomized Trial: Low-Dose Corticosteroids for Short Periods Effective and Safe for Hand Osteoarthritis

#ACR19 – [Not Published Yet] Randomized Trial: Methotrexate May Reduce Joint Damage Progression in Erosive Hand Osteoarthritis

Research: Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis

Podcast | Myositis and myopathy.

24 Aug, 2022 | 14:04h | UTC

#348 Myositis and Myopathy, LIVE! – The Curbsiders

Systematic Review | There is insufficient evidence to recommend running shoes for preventing lower limb running injuries in adults.

23 Aug, 2022 | 13:00h | UTC

Running shoes for preventing lower limb running injuries in adults – Cochrane Library

Summary: Running shoes for preventing lower-limb running injuries in adults – Cochrane Library

Commentary on Twitter

👟Running shoes have been proposed as one means of reducing injury risk….but are they effective? @CochraneBJMT authors looked at 12 trials that lasted 6-26 wks with 11,240 people. https://t.co/09bt9SzEkh pic.twitter.com/qi5qk7W1I1

— The Cochrane Library (@CochraneLibrary) August 22, 2022